This Fitness Tech Stock Has Crushed Apple's 2025 Gains -- 1 Reason Why

Zepp Health (NYSE: ZEPP) reported its first overall revenue growth since 2021, with Q2 2025 revenue reaching $59 million, a 46% year-over-year increase, driven entirely by its proprietary Amazfit wearable products. This significant turnaround follows a strategic pivot in 2021 to transition away from Xiaomi-branded devices and focus on its own Amazfit brand, a move that has seen its stock surge over 1,900% in 2025, despite the company remaining unprofitable.

Analysis

Zepp Health (NYSE: ZEPP) has reported its first overall revenue growth since 2021, with Q2 2025 revenue reaching $59 million, marking a substantial 46% year-over-year increase. This significant turnaround follows a strategic pivot initiated in 2021 to transition away from its reliance on partner Xiaomi and focus entirely on its proprietary Amazfit brand of wearable technology. The market has reacted strongly to this shift, with ZEPP's stock surging over 1,900% year-to-date as of October 16, contrasting sharply with Apple's (AAPL) recent 1% decline in the wearables segment.

The reported revenue growth was entirely driven by Amazfit products, validating the company's independent brand strategy and its investment in brand building, including endorsements from elite athletes like Derrick Henry. This successful execution of a risky strategic move has transformed the company's outlook from consistent share price and revenue declines to robust expansion.

Despite the impressive revenue growth and stock performance, Zepp Health remains an unprofitable entity, indicating ongoing operational challenges or significant reinvestment into growth. This positions ZEPP as a higher-risk, higher-reward opportunity compared to established, steady performers, with its long-term sustainability contingent on achieving profitability.

Key Decisions for Investors

• Investors seeking high-growth, high-risk exposure in the wearables sector should consider Zepp Health, acknowledging its current unprofitability despite strong revenue expansion.
• Monitor Zepp Health's upcoming earnings reports for continued Amazfit-driven revenue growth and any progress towards profitability, which would further validate the strategic pivot.
• Evaluate Zepp Health's competitive positioning and market share gains against established players, recognizing its potential for significant upside but also higher volatility given its smaller size and turnaround phase.